(Q46023795)

English

Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.

scientific article published in January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

1 reference

based on heuristic

inferred from title

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

Victoria Cornelius

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

author name string

Veronika Vlckova

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

Rachna Kasliwal

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

Lynda Wilton

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

Saad A W Shakir

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

32

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

409-418

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

https://scigraph.springernature.com/pub.10.2165/00002018-200932050-00004

0 references

Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic compliance: a prospective analysis of various factors involved in the adherence rate in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral antidiabetic medication adherence and glycemic control in managed care.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19419235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00002018-200932050-00004

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19419235

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46023795&oldid=1512246703"